editor 
May 09AztecgoldmegawaysslotThe share price of Wushi (300357) rose sharply.AztecgoldmegawaysslotAs of 10:50, our military biology is up 5%.Aztecgoldmegawaysslot.10%, at 27Aztecgoldmegawaysslot.63 yuan per share, a new high in nearly 4 months, with a turnover of 268 million yuan and a turnover rate of 2.12%.
News interpretation
The concept of A-share synthetic biology has attracted the attention of market funds, and the attention of the biomedical sector has also continued to rise in the near future. However, many medical and biological theme funds, industry index funds and other products have frequently appeared winding-up crises recently. It is worth noting that many varieties of related products in the first quarter have risen sharply in the last three months, but this has not given a boost to the scale of the products, and some funds have been established for less than a year.
Recently, pharmaceutical stocks have continued to improve, and the general feedback from the industry is due to the insertion of the "wings" of synthetic biology. Driven by the concept of synthetic biology, the share prices of many leading pharmaceutical companies have risen sharply recently. Stocks such as Azure Biology, Lukang Medicine, Chuanning Biology, Xinghu Science and Technology, and Bepsese are all varieties with high awareness of the concept of synthetic biology, and the synthetic biological index has also risen sharply in the past half a month, with an increase of 24.52% from April 22 to May 7.
May 8 news, Luoyang Huizhong Hongtai venture capital fund partnership (limited partnership) has been put on record in the China Foundation Association a few days ago. The fund contributed 200 million yuan, and its partners included Preco Biological Engineering Co., Ltd., Luoyang Industrial Development Fund Partnership (limited partnership) and Luoyang Huizhong Private Equity Fund Management Co., Ltd., with a direct shareholding of 59%, 40% and 1%, respectively. Among them, Luoyang Industrial Development Fund is a fund under Luoyang Guohong Investment holding Group. This is the first biomedical CVC fund in Luoyang. The establishment of the fund is a powerful measure for Luoyang Guohong Investment and Control Group to help Luoyang speed up the construction of five advanced manufacturing clusters, focusing on building 17 superior industrial chains. It is also a new exploration in the CVC fund model, creating a new paradigm of "listed companies + state-owned capital + industrial cultivation", filling in the gap in the field of Luoyang biomedical fund.
In addition, data statistics show that in the past half a year, 2 brokerages have given suggestions to increase their holdings and 2 brokerages have given buying suggestions.
Capital trend
As of press time, I Wushi got a net outflow of 21.11 million yuan, of which 9.98 million yuan was from a super-large unit and 11.11 million yuan from a large one. Data show that the net inflow of the stock today is 21.37 million yuan lower than the average net inflow of nearly 5 days.
In terms of margin trading, Wushi received a net purchase of 5.09 million yuan on May 07, and the financing balance of the stock on that day was 293 million yuan, which increased by 1.77% over the previous day, achieving two consecutive increases; the margin balance of the stock was 9.4 million yuan, and the margin margin was 340200 shares, an increase of 4.16% over the previous day. As of May 07, the stock had a total margin balance of 301 million yuan.
In terms of northbound funds, Wushi received northbound funds to increase its holdings by 26000 shares on May 08. As of May 08, Beixiang funds currently hold a total of 3.6824 million shares, with a market capitalization of 102 million yuan, accounting for 0.70% of the outstanding shares.
Main business and performance
Our main business is engaged in the R & D, production and sales of allergic disease diagnosis and treatment products.
According to the latest financial report, in the first quarter of this year, Wushi achieved operating income of 216 million yuan, an increase of 18.08% over the same period last year, and a net profit of 77.2073 million yuan, an increase of 9.55% over the same period last year, and basic earnings per share was 0.15 yuan.
(the above content is Portfolio based on public information, intelligently generated by programs or algorithms, only as a reference for users to view the market, not as investment advice or transaction basis. The stock market is risky, please make a careful decision. )